367 related articles for article (PubMed ID: 28332883)
21. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
[TBL] [Abstract][Full Text] [Related]
22. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
[TBL] [Abstract][Full Text] [Related]
23. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.
Butz JJ; Yan Q; McKenzie TJ; Weingarten TN; Cavalcante AN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
Surgery; 2017 Dec; 162(6):1259-1269. PubMed ID: 28919049
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
25. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
26. Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.
Nakamura E; Kaelin WG
Endocr Pathol; 2006; 17(2):97-106. PubMed ID: 17159241
[TBL] [Abstract][Full Text] [Related]
27. Genetic testing for pheochromocytoma-associated syndromes.
Pawlu C; Bausch B; Reisch N; Neumann HP
Ann Endocrinol (Paris); 2005 Jun; 66(3):178-85. PubMed ID: 15988378
[TBL] [Abstract][Full Text] [Related]
28. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.
Opocher G; Conton P; Schiavi F; Macino B; Mantero F
Fam Cancer; 2005; 4(1):13-6. PubMed ID: 15883705
[TBL] [Abstract][Full Text] [Related]
29. Familial pheochromocytoma.
Erlic Z; Neumann HP
Hormones (Athens); 2009; 8(1):29-38. PubMed ID: 19269919
[TBL] [Abstract][Full Text] [Related]
30. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
31. Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
Kuo MJM; Nazari MA; Jha A; Pacak K
Front Endocrinol (Lausanne); 2022; 13():936178. PubMed ID: 35903274
[TBL] [Abstract][Full Text] [Related]
32. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma.
Galan SR; Kann PH
Clin Endocrinol (Oxf); 2013 Feb; 78(2):165-75. PubMed ID: 23061808
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Huynh TT; Pacak K; Wong DL; Linehan WM; Goldstein DS; Elkahloun AG; Munson PJ; Eisenhofer G
Ann N Y Acad Sci; 2006 Aug; 1073():241-52. PubMed ID: 17102092
[TBL] [Abstract][Full Text] [Related]
34. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
35. [Genetics of pheochromocytoma and the relevance in surgery].
von Dobschütz E; Neumann HPH
Chirurg; 2019 Jan; 90(1):15-22. PubMed ID: 30306232
[TBL] [Abstract][Full Text] [Related]
36. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
39. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.
Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167
[TBL] [Abstract][Full Text] [Related]
40. Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
Smestad JA; Maher LJ
BMC Cancer; 2019 Jun; 19(1):619. PubMed ID: 31234811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
